Hezhong Y. Chen
Changhai Road
Shanghai, 200433, China
Shanghai, 200433, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications
LEF1/NFE2L3/TACC1 axis activates the AKT-mTOR pathway to promote the progression of esophageal squamous cell carcinoma.
Journal: Journal of thoracic disease
Published: March 23, 2026
Robot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trial.
Journal: The lancet. Gastroenterology & hepatology
Published: October 24, 2025
A METTL3-NFE2L3 axis mediates tumor stemness and progression in lung adenocarcinoma.
Journal: Science advances
Published: April 18, 2025
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study.
Journal: Journal of hematology & oncology
Published: December 21, 2024
FOXA2 suppresses ESCC proliferation and metastasis by inhibiting PSMB9 expression, thereby attenuating proteasome activity.
Journal: Cancer cell international
Published: July 31, 2024
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study.
Journal: Journal of hematology & oncology
Published: April 05, 2024
A case of congenital bronchial atresia with tracheobronchial stenosis caused by emphysema: Successful management with thoracoscopic surgery.
Journal: Heliyon
Published: February 27, 2024
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study.
Journal: Signal transduction and targeted therapy
Published: October 30, 2023
Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study.
Journal: The Journal of thoracic and cardiovascular surgery
Published: June 11, 2023
Genome-wide methylation profiling identified methylated KCNA3 and OTOP2 as promising diagnostic markers for esophageal squamous cell carcinoma.
Journal: Chinese medical journal
Published: April 12, 2023
Utility of 18F-FDG PET/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 18, 2022
Correction to: The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
Journal: Cancer immunology, immunotherapy : CII
Published: September 20, 2022
Last Updated: 09/26/2026